Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece

Hellenic Journal of Cardiology

Volumn 46, Issue 3, 2005, Pages 212-221

  Maniadakis, Nikolaos ^a,d   Kaitelidou, Daphne ^b   Siskou, Olga ^b   Spinthouri, Maria ^b   Liaropoulos, Lycourgos ^b   Fragoulakis, Basilis ^a   Hatzikou, Magda ^c   Alexopoulos, Dimetrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Health Economics ^*  (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Acute myocardial infarction; Cost effectiveness analysis; Economic evaluation; Thrombolytic drugs

Indexed keywords

ALTEPLASE; RETEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; GREECE; HEART REINFARCTION; HOSPITALIZATION; HUMAN; LIFESPAN; REVIEW; STROKE; SURVIVAL; SYSTEMATIC REVIEW; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EVALUATION; FEMALE; HEART INFARCTION; MALE; MIDDLE AGED; MORTALITY; STATISTICAL MODEL; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FIBRINOLYTIC AGENTS; GREECE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 24644477142     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
2. European Society of Cardiology and the European Resuscitation Council: The pre-hospital management of acute heart attacks: Recommendations of a task force of the European Society of Cardiology and the European Resuscitation Council. Eur Heart J 1998; 19: 1140-1164.
3. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
4. American Heart Association (AHA). 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association 1999; 10-12.
5. British Heart Foundation. Coronary Heart Disease Statistics. Economics Supplement. Oxford, 1998.
6. Liu J L Y, Maniadakis N, Gray A, et al: The economic burden of coronary heart disease in the UK. Heart 2002; 88: 597-603.
7. Center for Health Services Management & Evaluation Group, Dept. of Nursing, University of Athens: Treatment, costs and outcomes of ischaemic heart disease in Greece. In: OECD study of cross-national differences in the treatment, costs and outcomes of ischaemic heart disease. OECD; 2001: DEELSA/ELSA/WP1 (2001)7.
8. United Kingdom Heart Attack Study (UKHAS) Collaborative Group: Effect of time from onset to coming under care on fatality of patients with acute myocardial infarction: effect of resuscitation and thrombolytic treatment. Heart 1998; 80: 114-120.
9. Boersma E, Mass A, Deckers J, et al: Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775.
10. Newby K: Clinical outcomes according to time to treatment. Clin Cardiol 1997; 20 (11 Suppl. 3): III11-15.
11. Weaver WD: Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol 1995; 25 (7 Suppl): 3S-9S.
12. Goel V, Naylor CD: Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol 1992; 8: 31-38.
13. Kalish SC, Gurwitz JH, Krumholz HM, et al: A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10: 321-330.
14. Kellett J: Cost-effectiveness of accelerated tissue plasminogen activator for acute myocardial infarction. British Journal of Medical Economics 1996; 341-359.
15. Lorenzoni R, Pagano D, Mazzotta G, et al: Pitfalls in the economic evaluation of thrombolysis in myocardial infarction: the impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Eur Heart J 1998; 19: 1518-1524.
16. Mark DB, Hlatky MA, Califf RM, et al: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1424.
17. Massel D: Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Can J Cardiol 1999; 15: 173-179.
18. Naylor CD, Bronskill S, Goel V: Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993; 9: 553-558.
19. Pelc A, Dardenne J, Frelon JH, et al: Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting. Pharmacoeconomics 1997; 11: 595-605.
20. Boland A, Dundan Y, Bagust A, et al.. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technology Assessment, vol. 7, no 15, 2003 (http://www.ncchta.org/project.asp? PjtId=1273).
21. Khan K, Ter Riet G, Glanville J, et al: Undertaking systematic reviews of research on effectiveness. CRD guidance for carrying out or commissioning reviews. 2nd rev. ed. CRD Report 4. NHS Centre for Reviews and Dissemination (CRD), York: University of York, 2000.
22. GUSTO III Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-1123.
23. Van de Werf F, Adgey J, Ardissino D, et al: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
24. Capewell S, Livingston BM, MacIntyre K, et al: Trends in case-fatality in 117718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000; 21: 1833-1840.
25. Topol EJ, Ohman EM, Armstrong PW, et al: Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: Results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial. Circulation 2000; 102: 1761-1765.
26. Sinnaeve P, Granger C, Barbash G, et al: Single bolus tenecteplase and front loaded alteplase remain equivalent after one year: follow up results of the ASSENT 2 trial. XXII Congress of the European Society of Cardiology. Eur Heart J 2000; 21 (Suppl. 481), abstr 2582.
27. van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.